|
atrial fibrillation |
32 |
|
heart failure |
28 |
|
humans |
23 |
|
atherosclerosis |
22 |
|
coronary artery disease |
22 |
|
ischemic stroke |
22 |
|
type 2 diabetes mellitus |
22 |
|
endothelial progenitor cells |
21 |
|
female |
21 |
|
male |
21 |
|
middle aged |
20 |
|
type 2 diabetes |
20 |
|
myocardial infarction |
19 |
|
tricuspid annuloplasty |
19 |
|
rheumatoid arthritis |
18 |
|
bnt162b2 |
16 |
|
coronavac |
16 |
|
covid-19 vaccine |
16 |
|
echocardiography |
16 |
|
secondary prevention |
16 |
|
vaccine safety |
16 |
|
cardiovascular diseases |
15 |
|
aged |
14 |
|
risk factors |
14 |
|
adult |
13 |
|
cardiovascular magnetic resonance |
13 |
|
25-hydroxyvitamin d |
12 |
|
case-control studies |
12 |
|
endothelial function |
12 |
|
incidence |
12 |
|
inflammation |
12 |
|
mortality |
12 |
|
adverse outcome |
11 |
|
cardiac function |
11 |
|
carotid intima-media thickness |
11 |
|
cross-sectional studies |
11 |
|
endothelial dysfunction |
11 |
|
medical sciences |
11 |
|
pericarditis |
11 |
|
tricuspid regurgitation |
11 |
|
trimetazidine |
11 |
|
valvular heart disease |
11 |
|
genetic polymorphism |
10 |
|
inactivated vaccine |
10 |
|
incident cvd |
10 |
|
long covid |
10 |
|
omicron |
10 |
|
periodontitis |
10 |
|
post-covid cvd |
10 |
|
sars-cov-2 |
10 |
|
sex difference |
10 |
|
vascular function |
10 |
|
vitamin d-binding protein |
10 |
|
biological markers - blood |
9 |
|
dementia |
9 |
|
garlic |
9 |
|
hfpef |
9 |
|
outcome |
9 |
|
prevalence |
9 |
|
prognosis |
9 |
|
retrospective studies |
9 |
|
self-controlled case series |
9 |
|
stroke |
9 |
|
4d flow |
8 |
|
adverse events of special interest |
8 |
|
cha2ds2-vasc |
8 |
|
chads2 |
8 |
|
cirrhosis |
8 |
|
covid-19 vaccines |
8 |
|
direct flow |
8 |
|
endothelial cells - pathology |
8 |
|
flow cytometry |
8 |
|
high-sensitivity troponin i |
8 |
|
imaging |
8 |
|
intraventricular flow |
8 |
|
liver transplantation |
8 |
|
multi-detector computed tomography |
8 |
|
myocarditis |
8 |
|
residual volume |
8 |
|
stem cells - pathology |
8 |
|
trs 2°p |
8 |
|
valvular surgery |
8 |
|
vascular markers of atherosclerosis |
8 |
|
adipocytes - metabolism - pathology |
7 |
|
ankle brachial index |
7 |
|
arterial calcification |
7 |
|
arterial stiffness |
7 |
|
arthritisosteogenesis |
7 |
|
blood flow velocity |
7 |
|
body mass index |
7 |
|
bone–vascular axis |
7 |
|
brain ischemia - blood - diagnosis - mortality |
7 |
|
calcification |
7 |
|
cardio-oncology |
7 |
|
circulating endothelial progenitor cells |
7 |
|
conduction disorders |
7 |
|
coronary angiography |
7 |
|
coronary vessels - pathology |
7 |
|
diabetes |
7 |
|
dietary supplements |
7 |
|
drug repositioning |
7 |
|
electrocardiography |
7 |
|
endothelial progenitor cell |
7 |
|
fatty acid-binding proteins - blood |
7 |
|
hong kong |
7 |
|
ischemic heart disease |
7 |
|
isoflavone |
7 |
|
left ventricular function |
7 |
|
lung cancer |
7 |
|
major adverse cardiovascular events |
7 |
|
metabolic re-programming |
7 |
|
myocardial injury |
7 |
|
osteocalcin |
7 |
|
osteogenic endothelial progenitor cells |
7 |
|
pleiotropic effects |
7 |
|
pr prolongation |
7 |
|
psoriasis |
7 |
|
pulmonary hypertension |
7 |
|
questionnaires |
7 |
|
rheumatoid |
7 |
|
sglt2 inhibitors |
7 |
|
statin |
7 |
|
statin therapy |
7 |
|
stem cells - physiology |
7 |
|
stroke - blood - diagnosis - mortality |
7 |
|
systemic lupus erythematosus |
7 |
|
adverse cardiovascular events |
6 |
|
adverse cardiovascular outcomes |
6 |
|
aging - immunology - metabolism |
6 |
|
antihypertensive drugs |
6 |
|
aorta, thoracic - pathology - radiography |
6 |
|
aortic diseases - epidemiology - radiography |
6 |
|
arterial stiffiness |
6 |
|
arthritis, rheumatoid - complications |
6 |
|
arthritis, rheumatoid - complications - immunology - physiopathology |
6 |
|
asymptomatic |
6 |
|
atherosclerosis - epidemiology - physiopathology - radiography |
6 |
|
atherosclerosis - epidemiology - radiography |
6 |
|
atrial fibrillation - complications |
6 |
|
atrioventricular block - complications - diagnosis - physiopathology |
6 |
|
bleeding |
6 |
|
brachial artery - pathology |
6 |
|
brachial artery - physiopathology |
6 |
|
brachial artery - physiopathology - ultrasonography |
6 |
|
brain ischemia - epidemiology - etiology |
6 |
|
c-reactive protein |
6 |
|
calcinosis - complications - epidemiology - radiography |
6 |
|
calcinosis - epidemiology - physiopathology - radiography |
6 |
|
cancer |
6 |
|
cardiovascular continuum |
6 |
|
cardiovascular death |
6 |
|
cardiovascular diseases - blood - diet therapy - prevention & control |
6 |
|
cardiovascular diseases - epidemiology - physiopathology - radiography |
6 |
|
cardiovascular diseases - etiology |
6 |
|
cardiovascular diseases - etiology - physiopathology |
6 |
|
cardiovascular event |
6 |
|
cardiovascular mortality |
6 |
|
cardiovascular system - pathology - physiopathology - radiography |
6 |
|
carotid arteries - pathology - radiography |
6 |
|
carotid artery diseases - epidemiology - radiography |
6 |
|
carotid artery diseases - epidemiology - ultrasonography |
6 |
|
chads2 and cha2ds2-vasc scores |
6 |
|
comorbidity |
6 |
|
computer tomography |
6 |
|
confounding factors (epidemiology) |
6 |
|
coronary artery calcium |
6 |
|
coronary artery disease - epidemiology - immunology - physiopathology |
6 |
|
coronary artery disease - epidemiology - radiography |
6 |
|
deficiency diseases - complications - physiopathology |
6 |
|
diet |
6 |
|
diet records |
6 |
|
drug interaction |
6 |
|
endothelial cells - cytology - physiology |
6 |
|
endothelium, vascular - cytology - physiology |
6 |
|
endothelium, vascular - immunology - pathology |
6 |
|
endothelium, vascular - physiopathology |
6 |
|
energy intake |
6 |
|
estimated glomerular filtration rate |
6 |
|
exercise capacity |
6 |
|
follow-up studies |
6 |
|
high cardiovascular risk |
6 |
|
high sensitive troponin level |
6 |
|
hyperthyroidism |
6 |
|
hyperthyroidism - complications |
6 |
|
liver stiffness |
6 |
|
lupus erythematosus, systemic - complications - physiopathology |
6 |
|
mesenchymal stem cells - immunology - pathology |
6 |
|
mitral valve |
6 |
|
multidetector computed tomography |
6 |
|
multinational cohort study |
6 |
|
non-st elevated myocardial infarction |
6 |
|
nonvalvular atrial fibrillation |
6 |
|
non–vitamin k oral anticoagulant |
6 |
|
nutrition |
6 |
|
nutrition assessment |
6 |
|
obesity |
6 |
|
older people |
6 |
|
pathophysiological mechanism |
6 |
|
peripheral artery disease |
6 |
|
phytoestrogen |
6 |
|
phytoestrogens - administration & dosage |
6 |
|
pr interval prolongation |
6 |
|
proportional hazards models |
6 |
|
prospective studies |
6 |
|
psoriasis - epidemiology |
6 |
|
recurrent stroke |
6 |
|
renal dysfunction |
6 |
|
risk |
6 |
|
risk prediction |
6 |
|
screening |
6 |
|
selenium - administration & dosage - deficiency |
6 |
|
selenium deficiency |
6 |
|
st segment elevation myocardial infarction |
6 |
|
statin intolerance |
6 |
|
stress cardiac magnetic resonance |
6 |
|
timi grading system |
6 |
|
tomography, spiral computed |
6 |
|
trace elements - deficiency |
6 |
|
vascular calcification |
6 |
|
vascular diseases - etiology - physiopathology |
6 |
|
vascular dysfunction |
6 |
|
vasodilation |
6 |
|
ace2 |
5 |
|
acei |
5 |
|
acute kidney injury |
5 |
|
adenosine triphosphate |
5 |
|
adult cardiology |
5 |
|
aged, 80 and over |
5 |
|
antigens, cd34 - analysis |
5 |
|
arb |
5 |
|
arrhythmia |
5 |
|
arteries - pathology |
5 |
|
arteriosclerosis - etiology - pathology - ultrasonography |
5 |
|
arthritis, rheumatoid - complications - pathology - physiopathology |
5 |
|
axial spondyloarthritis |
5 |
|
bdmards |
5 |
|
brachial artery - drug effects - physiology |
5 |
|
c-reactive protein - metabolism |
5 |
|
calcinosis - epidemiology - etiology - pathology |
5 |
|
cardiac dysfunction |
5 |
|
cardiac function reserve |
5 |
|
cardiovascular |
5 |
|
cardiovascular risk |
5 |
|
cardiovascular safety of biologics |
5 |
|
carotid arteries - pathology |
5 |
|
carotid arteries - pathology - ultrasonography |
5 |
|
cell count |
5 |
|
chronic kidney disease |
5 |
|
clinical pharmacology |
5 |
|
cohort studies |
5 |
|
computed tomography |
5 |
|
coronary calcification |
5 |
|
diabetes mellitus |
5 |
|
diabetes mellitus, type 2 - pathology - physiopathology |
5 |
|
diabetic cardiomyopathy |
5 |
|
diabetic retinopathy |
5 |
|
diastolic function |
5 |
|
effective regurgitant orifice area (eroa) |
5 |
|
electronics |
5 |
|
endothelium, vascular - drug effects |
5 |
|
endothelium, vascular - pathology - ultrastructure |
5 |
|
exercise echocardiography |
5 |
|
flow-mediated dilatation |
5 |
|
gene expression |
5 |
|
heart valve diseases - epidemiology - etiology - pathology |
5 |
|
hong kong - epidemiology |
5 |
|
isoflavones - administration and dosage - therapeutic use |
5 |
|
jak inhibitors |
5 |
|
left ventricular longitudinal strain |
5 |
|
left-sided valve disease |
5 |
|
liver and renal dysfunction |
5 |
|
lupus erythematosus, systemic - complications - pathology - physiopathology |
5 |
|
metabolic disorders |
5 |
|
model for end-stage liver disease |
5 |
|
percutaneous coronary intervention |
5 |
|
periodontal disease |
5 |
|
prevention |
5 |
|
randomized clinical trial |
5 |
|
real-world observational study |
5 |
|
rheumatic valvular heart disease |
5 |
|
saliva |
5 |
|
sex |
5 |
|
soybean proteins - therapeutic use |
5 |
|
stress |
5 |
|
stroke - pathology |
5 |
|
systemic calcified atherosclerosis |
5 |
|
systemic conditions |
5 |
|
t-wave alternans |
5 |
|
tmprss2 |
5 |
|
treatment outcome |
5 |
|
tricuspid regurgitation (tr) |
5 |
|
tricuspid valve insufficiency |
5 |
|
tunica intima - pathology |
5 |
|
tunica intima - ultrasonography |
5 |
|
tunica media - ultrasonography |
5 |
|
valvular calcification |
5 |
|
vascular resistance |
5 |
|
vitamin d |
5 |
|
vitamin d deficiency - pathology |
5 |
|
abc pathway |
4 |
|
acute coronary syndrome |
4 |
|
adipocyte fatty acid-binding protein |
4 |
|
adipokines |
4 |
|
af |
4 |
|
afabp |
4 |
|
amiodarone - adverse effects |
4 |
|
analysis of variance |
4 |
|
anti-arrhythmia agents - adverse effects |
4 |
|
antigens, cd - metabolism |
4 |
|
arthroplasty |
4 |
|
article |
4 |
|
asian continental ancestry group |
4 |
|
atrial high rate |
4 |
|
atrioventricular block - therapy |
4 |
|
biological markers |
4 |
|
blood pressure |
4 |
|
blood pressure - drug effects - physiology |
4 |
|
bone marrow cells |
4 |
|
cardiac pacing, artificial - adverse effects - methods |
4 |
|
cardiac pacing, artificial - methods |
4 |
|
cardiovascular disease |
4 |
|
cardiovascular diseases - blood - diagnosis - mortality |
4 |
|
cardiovascular diseases - epidemiology - metabolism |
4 |
|
cardiovascular diseases - ethnology - etiology |
4 |
|
cardiovascular diseases - mortality |
4 |
|
cardiovascular outcomes |
4 |
|
chemicals and cas registry numbers |
4 |
|
china |
4 |
|
co-enzyme q10 |
4 |
|
community-acquired infections - epidemiology - microbiology |
4 |
|
congestive heart failure |
4 |
|
coronary artery disease - diagnosis - epidemiology |
4 |
|
coronary artery disease - pathology |
4 |
|
coronary artery disease - physiopathology |
4 |
|
coronary artery disease - physiopathology - rehabilitation |
4 |
|
coronary artery disease - ultrasonography |
4 |
|
coronary heart disease |
4 |
|
cross-talk |
4 |
|
crt |
4 |
|
cryptogenic |
4 |
|
cytokines |
4 |
|
diabetes mellitus - physiopathology |
4 |
|
diabetes mellitus, type 2 - blood - diagnosis - mortality |
4 |
|
diet surveys |
4 |
|
dinoprost - analogs & derivatives - blood |
4 |
|
disease activity |
4 |
|
disease association |
4 |
|
doppler echocardiography |
4 |
|
double-blind method |
4 |
|
dpp-4 inhibitors |
4 |
|
dvr |
4 |
|
echocardiography, doppler |
4 |
|
end-stage renal disease |
4 |
|
endocarditis, bacterial - epidemiology - microbiology |
4 |
|
endocarditis, bacterial - microbiology |
4 |
|
endothelial cells |
4 |
|
endothelial cells - physiology |
4 |
|
endothelium cell |
4 |
|
endothelium, vascular - drug effects - physiology |
4 |
|
endothelium, vascular - metabolism |
4 |
|
endothelium, vascular - metabolism - pathology |
4 |
|
endothelium, vascular - physiology |
4 |
|
exercise |
4 |
|
exercise - physiology |
4 |
|
flow-mediated dilation |
4 |
|
glycoproteins - metabolism |
4 |
|
gram-positive bacterial infections |
4 |
|
health surveys |
4 |
|
heart diseases |
4 |
|
heart diseases - complications - diagnosis |
4 |
|
heart failure - diagnosis - prevention & control |
4 |
|
heart failure - epidemiology - etiology - therapy |
4 |
|
heart right ventricle |
4 |
|
heart ventricles - ultrasonography |
4 |
|
hemodynamics - physiology |
4 |
|
heparin |
4 |
|
hepatokines |
4 |
|
hf |
4 |
|
high-sensitivity troponin i outcome |
4 |
|
hip |
4 |
|
hip fractures - surgery |
4 |
|
human |
4 |
|
hypercholesterolemia - physiopathology |
4 |
|
hypertension |
4 |
|
hypertension - ultrasonography |
4 |
|
hypertension, pulmonary - diagnosis - prevention & control |
4 |
|
hypertension, pulmonary - physiopathology |
4 |
|
hyperuricaemia |
4 |
|
implantable cardioverter-defibrillater |
4 |
|
implanted pacemaker |
4 |
|
infection |
4 |
|
infective endocarditis |
4 |
|
insertable cardiac monitor |
4 |
|
integrated care |
4 |
|
interleukins |
4 |
|
ischemia |
4 |
|
ischemic cardiomyopathy |
4 |
|
isoflavones - administration & dosage |
4 |
|
kidney failure, chronic - physiopathology - therapy |
4 |
|
knee |
4 |
|
lactococcus |
4 |
|
left ventricular dysfunction |
4 |
|
left ventricular dyssynchrony |
4 |
|
lipid metabolism - drug effects - physiology |
4 |
|
longitudinal cardiac change |
4 |
|
low-molecular-weight |
4 |
|
lung artery pressure |
4 |
|
lung vascular resistance |
4 |
|
major clinical study |
4 |
|
masld |
4 |
|
metabolic reprogramming |
4 |
|
metabolic syndrome x - complications - ethnology |
4 |
|
mitochondrial function |
4 |
|
multivariate analysis |
4 |
|
nitroglycerin - metabolism |
4 |
|
nitroglycerin-mediated dilatation |
4 |
|
osteoporosis |
4 |
|
osteoporotic fractures - surgery |
4 |
|
oxygen consumption - physiology |
4 |
|
pacing |
4 |
|
peptides - metabolism |
4 |
|
peritoneal dialysis |
4 |
|
physical activity level |
4 |
|
physical endurance - physiology |
4 |
|
placebos |
4 |
|
post-stroke care |
4 |
|
postoperative complications/prevention & control |
4 |
|
preoperative care - methods |
4 |
|
priority journal |
4 |
|
progenitor cells |
4 |
|
pulmonary artery |
4 |
|
pulmonary artery - ultrasonography |
4 |
|
pulmonary artery systolic pressure |
4 |
|
pulse wave velocity |
4 |
|
regional wall motion abnormality |
4 |
|
registries |
4 |
|
renin–angiotensin–aldosterone system |
4 |
|
replacement |
4 |
|
rheumatic diseases - complications - ethnology |
4 |
|
rheumatic heart disease - epidemiology |
4 |
|
risk assessment |
4 |
|
sleep apnea, central - diagnosis - prevention & control |
4 |
|
smoking |
4 |
|
smoking - adverse effects |
4 |
|
soybean proteins - administration & dosage |
4 |
|
soybeans - chemistry |
4 |
|
spinal cord stimulation |
4 |
|
staphylococcus aureus |
4 |
|
stem cell |
4 |
|
stem cells |
4 |
|
stem cells - metabolism - pathology |
4 |
|
strain rate |
4 |
|
substance abuse, intravenous - epidemiology |
4 |
|
sudden death |
4 |
|
superoxide dismutase - blood |
4 |
|
surgery |
4 |
|
surgical |
4 |
|
systemic sclerosis |
4 |
|
systolic blood pressure |
4 |
|
tachycardia, ventricular - diagnosis - epidemiology |
4 |
|
three-dimensional echocardiography |
4 |
|
thyrotoxicosis - chemically induced |
4 |
|
time factors |
4 |
|
tricuspid valve geometry |
4 |
|
troponin i - blood |
4 |
|
tunica intima - pathology - ultrasonography |
4 |
|
tunica media - pathology - ultrasonography |
4 |
|
ubiquinone - administration & dosage - analogs & derivatives - metabolism |
4 |
|
uric acid |
4 |
|
valves |
4 |
|
vascular smooth muscle cells |
4 |
|
venous thromboembolism |
4 |
|
ventricular dysfunction, left - diagnosis - epidemiology |
4 |
|
ventricular dysfunction, left - epidemiology - etiology - therapy |
4 |
|
ventricular dysfunction, left - pathology |
4 |
|
ventricular dyssynchrony |
4 |
|
ventricular function, left - drug effects |
4 |
|
ventricular function, right - physiology |
4 |
|
*food habits |
3 |
|
*life style |
3 |
|
*motor activity |
3 |
|
*vascular stiffness |
3 |
|
administration, oral |
3 |
|
age factors |
3 |
|
angioplasty, balloon, coronary - adverse effects - instrumentation - mortality |
3 |
|
angioplasty, balloon, coronary - adverse effects - mortality |
3 |
|
anthracyclines |
3 |
|
anti-restenosis |
3 |
|
anti-thrombosis |
3 |
|
anticoagulants - adverse effects |
3 |
|
antigens, cd - blood |
3 |
|
antigens, cd34 - blood |
3 |
|
aortic valve |
3 |
|
aromatase inhibitors |
3 |
|
arteries - physiopathology |
3 |
|
asian continental ancestry group - statistics and numerical data |
3 |
|
atherosclerosis - etiology - physiopathology |
3 |
|
atrial flutter - surgery |
3 |
|
atrioventricular block |
3 |
|
atrioventricular block - physiopathology - therapy |
3 |
|
bacterial |
3 |
|
bifurcation lesions |
3 |
|
blood cells - cytology - metabolism |
3 |
|
blood coagulation disorders - chemically induced - drug therapy |
3 |
|
blood component transfusion |
3 |
|
blood glucose/metabolism |
3 |
|
blood volume |
3 |
|
body composition |
3 |
|
breast cancer |
3 |
|
c-reactive protein - analysis |
3 |
|
cardiac capacity |
3 |
|
cardiomegaly - complications - radiography - radionuclide imaging |
3 |
|
cardiorenal syndrome |
3 |
|
cardiorespiratory fitness |
3 |
|
cardiovascular diseases - etiology - mortality |
3 |
|
cardiovascular diseases/diagnosis/*etiology/physiopathology |
3 |
|
cardiovascular events |
3 |
|
catheter ablation - methods |
3 |
|
charlson comorbidity index |
3 |
|
checklist |
3 |
|
chronic periodontitis - blood |
3 |
|
chronic periodontitis - blood - therapy |
3 |
|
circulating haemoglobin mass |
3 |
|
clinical care pathways |
3 |
|
clinical correlates |
3 |
|
clinical trial |
3 |
|
clinical trials |
3 |
|
coagulants - administration & dosage |
3 |
|
coronary artery disease - complications - mortality - therapy |
3 |
|
coronary artery disease - drug therapy - physiopathology |
3 |
|
coronary artery disease - ethnology - mortality - radiography - therapy |
3 |
|
coronary artery disease/*blood/drug therapy/pathology/physiopathology |
3 |
|
delayed-action preparations |
3 |
|
diabetes mellitus, type 2 - complications - mortality |
3 |
|
dietary carbohydrates/*adverse effects |
3 |
|
disease susceptibility |
3 |
|
drug administration schedule |
3 |
|
drug therapy, combination |
3 |
|
drug-eluting stents |
3 |
|
dyslipidemias - drug therapy - physiopathology |
3 |
|
echocardiography parameters |
3 |
|
educational status |
3 |
|
electrocardiography. |
3 |
|
electrodes, implanted - adverse effects |
3 |
|
endocarditis |
3 |
|
endocarditis, bacterial - etiology - mortality - surgery |
3 |
|
endothelial cells - cytology - metabolism |
3 |
|
endothelium, vascular - drug effects - physiopathology |
3 |
|
endothelium, vascular/*metabolism/pathology/physiopathology |
3 |
|
epidemiological characteristics |
3 |
|
estrogen receptor |
3 |
|
f-18 fluorodeoxyglucose fdg |
3 |
|
fluorodeoxyglucose f18 - diagnostic use |
3 |
|
fragmented qrs |
3 |
|
gingival hemorrhage - blood |
3 |
|
gingival recession - blood |
3 |
|
glycoproteins - blood |
3 |
|
hans chinese |
3 |
|
hba1c variability |
3 |
|
heart failure - etiology - physiopathology - therapy |
3 |
|
heart failure with preserved ejection fraction |
3 |
|
heart valve diseases - surgery |
3 |
|
heart valve prosthesis |
3 |
|
heart valve prosthesis - adverse effects |
3 |
|
heart valve prosthesis implantation |
3 |
|
heart valve prosthesis implantation - adverse effects - instrumentation |
3 |
|
hepatorenal dysfunction |
3 |
|
high comorbidity burden |
3 |
|
hospital mortality |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects - pharmacology - therapeutic use |
3 |
|
hyperkalaemia |
3 |
|
hypolipidemic agents - adverse effects - pharmacology - therapeutic use |
3 |
|
implementation research |
3 |
|
indoles - adverse effects - pharmacology - therapeutic use |
3 |
|
infusions, intravenous |
3 |
|
international normalized ratio |
3 |
|
isosorbide dinitrate - administration & dosage - adverse effects - analogs & derivatives |
3 |
|
lactic acid/blood |
3 |
|
laropiprant |
3 |
|
lean body mass |
3 |
|
lipids/blood |
3 |
|
maces |
3 |
|
malnutrition |
3 |
|
mediastinum - radiography - radionuclide imaging |
3 |
|
metabolic syndrome |
3 |
|
metals |
3 |
|
microwaves - therapeutic use |
3 |
|
mitochondria, heart - drug effects - metabolism |
3 |
|
mitochondria/*metabolism/pathology |
3 |
|
mitochondrial diseases - chemically induced - metabolism |
3 |
|
mitochondrial dysfunction |
3 |
|
myocardial infarction - etiology |
3 |
|
niacin |
3 |
|
niacin - adverse effects - pharmacology - therapeutic use |
3 |
|
nitrate |
3 |
|
noncommunicable diseases |
3 |
|
nutritional status |
3 |
|
older age |
3 |
|
pathogeny |
3 |
|
peptides - blood |
3 |
|
pericarditis - complications - radiography - radionuclide imaging |
3 |
|
pericarditis - diagnosis - etiology |
3 |
|
periodontal attachment loss - blood |
3 |
|
periodontal diseases |
3 |
|
periodontal pocket - blood |
3 |
|
permanent pacemaker |
3 |
|
plasma |
3 |
|
positron emission tomography/computed tomography |
3 |
|
positron-emission tomography |
3 |
|
prediabetes |
3 |
|
pressure gradient manipulation |
3 |
|
prevalence in south-eastern chinese |
3 |
|
primary aldosteronism |
3 |
|
prosthesis-related infections |
3 |
|
prosthesis-related infections - etiology - mortality - surgery |
3 |
|
psoriasis - complications - physiopathology |
3 |
|
pulse wave analysis |
3 |
|
pyruvic acid/blood |
3 |
|
recurrence |
3 |
|
refractory hypertension |
3 |
|
regional adiposity |
3 |
|
renin-angiotensin-aldosterone system |
3 |
|
reoperation |
3 |
|
resistant hypertension |
3 |
|
restenosis |
3 |
|
right ventricular apex |
3 |
|
right ventricular apical pacing |
3 |
|
right ventricular function |
3 |
|
risk-stratification |
3 |
|
sepsis - etiology - mortality |
3 |
|
serum uric acid |
3 |
|
severity of illness index |
3 |
|
sex differ |
3 |
|
sex dimorphism |
3 |
|
sex factors |
3 |
|
simvastatin |
3 |
|
simvastatin - adverse effects - pharmacology - therapeutic use |
3 |
|
stem cells - cytology - metabolism |
3 |
|
strain |
3 |
|
surrogate marker |
3 |
|
tamoxifen |
3 |
|
target organ damage |
3 |
|
tomography, x-ray computed |
3 |
|
treatment inertia |
3 |
|
tunica media - pathology |
3 |
|
type 2 diabetic mellitus |
3 |
|
untreated hypertension |
3 |
|
vascular endothelial growth factor receptor-2 - blood |
3 |
|
vasodilator agents - administration & dosage - adverse effects |
3 |
|
venous return |
3 |
|
ventricular function, left - physiology |
3 |
|
vitamin k - administration & dosage |
3 |
|
waist-hip ratio |
3 |
|
warfarin - adverse effects |
3 |
|
*coronary angiography |
2 |
|
*drug-eluting stents |
2 |
|
ablation |
2 |
|
algorithms |
2 |
|
all-cause mortality |
2 |
|
aneurysm - etiology - radiography - ultrasonography |
2 |
|
angiocardiography |
2 |
|
angioplasty, balloon, coronary |
2 |
|
angioplasty, balloon, coronary - adverse effects - instrumentation - methods |
2 |
|
angiotensin ii type 1 receptor blockers - therapeutic use |
2 |
|
angiotensin-converting enzyme inhibitors - therapeutic use |
2 |
|
animals |
2 |
|
anthracycline |
2 |
|
anti-arrhythmia agents - therapeutic use |
2 |
|
antineoplastic agents, phytogenic - therapeutic use |
2 |
|
arrhythmias, cardiac - epidemiology - etiology - physiopathology - prevention & control |
2 |
|
arrhythmias, cardiac - epidemiology - physiopathology |
2 |
|
arterio-arterial fistula - radiography - surgery |
2 |
|
aspirin - therapeutic use |
2 |
|
atherosclerosis - etiology - metabolism - therapy - ultrasonography |
2 |
|
autonomics |
2 |
|
biomacromolecule |
2 |
|
biomarker |
2 |
|
biomarkers of extracellular matrix regulation and collagen turnover |
2 |
|
bone marrow cells - physiology |
2 |
|
bone marrow transplantation - physiology |
2 |
|
brachial artery - drug effects - physiopathology |
2 |
|
bypass surgery |
2 |
|
calcium - analysis |
2 |
|
calcium channel blockers - therapeutic use |
2 |
|
calibration |
2 |
|
cardiac imaging |
2 |
|
cardiomyopathies - therapy |
2 |
|
cardiopulmonary exercise test |
2 |
|
cardiopulmonary function |
2 |
|
cardiopulmonary resuscitation |
2 |
|
cardiotonic agents - adverse effects - diagnostic use |
2 |
|
cardiotonic agents/*administration & dosage |
2 |
|
cardiotoxicity |
2 |
|
cardiovascular agents/*administration & dosage |
2 |
|
cardiovascular disease in women |
2 |
|
cardiovascular diseases - drug therapy - physiopathology |
2 |
|
cardiovascular diseases - pathology - physiopathology - psychology |
2 |
|
cardiovascular stent coating |
2 |
|
cardiovascular system |
2 |
|
catheter ablation |
2 |
|
chemotherapy |
2 |
|
chi-square distribution |
2 |
|
chronic disease |
2 |
|
chronic kidney failure |
2 |
|
chronic myocardial ischemia |
2 |
|
clinical article |
2 |
|
cognitive impairment |
2 |
|
computational pressure-flow dynamics |
2 |
|
concomitant |
2 |
|
controlled study |
2 |
|
coronary artery bypass |
2 |
|
coronary artery bypass - adverse effects |
2 |
|
coronary artery disease (cad) |
2 |
|
coronary artery disease - pathology - therapy |
2 |
|
coronary bifurcation |
2 |
|
coronary disease - radiography - therapy |
2 |
|
coronary microvascular disease |
2 |
|
coronary occlusion - diagnosis |
2 |
|
coronary restenosis |
2 |
|
coronary restenosis - drug therapy - mortality - prevention & control |
2 |
|
coronary restenosis - etiology - prevention & control - radiography |
2 |
|
coronary restenosis/epidemiology |
2 |
|
coronary restenosis/etiology |
2 |
|
coronary stenosis - pathology - radiography - therapy |
2 |
|
coronary stenosis - radiography - therapy |
2 |
|
coronary stenosis/radiography/*therapy |
2 |
|
coronary stent |
2 |
|
coronary vasospasm - chemically induced - complications - physiopathology |
2 |
|
coronary vessels - surgery |
2 |
|
cortisol |
2 |
|
cytokines - therapeutic use |
2 |
|
death, sudden, cardiac - etiology |
2 |
|
depression |
2 |
|
depression - diagnosis |
2 |
|
diabetes mellitus, type 2 - drug therapy - physiopathology |
2 |
|
diagnosis, differential |
2 |
|
dipeptidyl peptidase-4 inhibitor |
2 |
|
dpp‐4 inhibitor |
2 |
|
drug eluting stent |
2 |
|
dual coronary fistulas |
2 |
|
echocardiography, doppler - methods |
2 |
|
editorial |
2 |
|
electrocardiogram |
2 |
|
electrocardiography - methods |
2 |
|
electrocardiography, ambulatory |
2 |
|
endothelial cells - pathology - physiology |
2 |
|
endothelial progenitor cells (epcs) |
2 |
|
endothelium, vascular - cytology - pathology - physiopathology |
2 |
|
endothelium-mimicking |
2 |
|
energy |
2 |
|
exercise test |
2 |
|
fatty acids, omega-3 - therapeutic use |
2 |
|
feasibility studies |
2 |
|
femoral vein |
2 |
|
fibrosis |
2 |
|
filter no reflow |
2 |
|
filtering surgery |
2 |
|
fish oil |
2 |
|
follow up |
2 |
|
fractional flow reserve |
2 |
|
gar |
2 |
|
global longitudinal strain |
2 |
|
glucose-albumin ratio |
2 |
|
graft occlusion, vascular - drug therapy - surgery - therapy |
2 |
|
graft occlusion, vascular - etiology - metabolism - therapy - ultrasonography |
2 |
|
graft occlusion, vascular - etiology - radiography - ultrasonography |
2 |
|
graft occlusion, vascular - radiography - therapy |
2 |
|
granulocyte macrophage colony-stimulating factor |
2 |
|
heart infarction |
2 |
|
heart left ventricle ejection fraction |
2 |
|
heart left ventricle failure |
2 |
|
heart ventricle arrhythmia |
2 |
|
hematopoietic stem cell mobilization |
2 |
|
hematopoietic stem cells (hscs) |
2 |
|
hemodynamics |
2 |
|
hypertension - complications - drug therapy |
2 |
|
hypertension-mediated organ damage |
2 |
|
hypertrophy, left ventricular - complications |
2 |
|
inferior wall myocardial infarction - diagnosis |
2 |
|
intensive care unit |
2 |
|
intravascular ultrasound |
2 |
|
isoproterenol - adverse effects - diagnostic use |
2 |
|
left atrial appendage closure |
2 |
|
left to right heart shunt |
2 |
|
left ventricular diastolic function |
2 |
|
linear models |
2 |
|
lipids - analysis |
2 |
|
logistic models |
2 |
|
long-term nitric oxide production |
2 |
|
low-density lipoprotein cholesterol |
2 |
|
mpri |
2 |
|
myocardial dysfunction |
2 |
|
myocardial infarction - therapy |
2 |
|
myocardial infarction/epidemiology |
2 |
|
myocardial infarction/etiology |
2 |
|
necrosis |
2 |
|
neovascularization, pathologic - therapy |
2 |
|
nitrates - therapeutic use |
2 |
|
no-reflow phenomenon - etiology - radiography - therapy |
2 |
|
non-dipper hypertension |
2 |
|
outcomes |
2 |
|
paclitaxel - administration & dosage |
2 |
|
paclitaxel - therapeutic use |
2 |
|
percutaneous coronary intervention/adverse effects/*instrumentation |
2 |
|
phlebograph - methods |
2 |
|
polyvascular disease |
2 |
|
population-based cohort study |
2 |
|
postoperative complications - etiology - therapy |
2 |
|
predictive value of tests |
2 |
|
predictors |
2 |
|
proportionality |
2 |
|
prosthesis design |
2 |
|
psychological tests |
2 |
|
pulmonary artery - radiography - surgery |
2 |
|
pulmonary fibrosis |
2 |
|
pulmonary vascular resistance |
2 |
|
re-endothelialization |
2 |
|
renal artery - drug effects - physiopathology |
2 |
|
renal function |
2 |
|
renin angiotensin system |
2 |
|
revascularization |
2 |
|
rheumatoid arthritis (ra) |
2 |
|
saphenous vein - chemistry - transplantation - ultrasonography |
2 |
|
saphenous vein - radiography - transplantation - ultrasonography |
2 |
|
saphenous vein - surgery - transplantation |
2 |
|
saphenous vein - transplantation |
2 |
|
saphenous vein graft |
2 |
|
saphenous vein graft intervention |
2 |
|
saphenous vien graft lesions |
2 |
|
scleroderma, systemic - epidemiology - physiopathology |
2 |
|
sensitivity and specificity |
2 |
|
sglt2 inhibitor |
2 |
|
sirolimus/administration & dosage/*analogs & derivatives |
2 |
|
sleeve technique |
2 |
|
sodium-glucose cotransporter 2 inhibitor |
2 |
|
speckle tracking strain |
2 |
|
statins |
2 |
|
stem cells - pathology - physiology |
2 |
|
stenting technique |
2 |
|
stents |
2 |
|
stress cmr |
2 |
|
stress, psychological - diagnosis - psychology |
2 |
|
survival rate |
2 |
|
syncope - diagnosis |
2 |
|
tachycardia, ventricular - drug therapy - etiology |
2 |
|
therapeutic gas |
2 |
|
thrombectomy - instrumentation - methods |
2 |
|
thromboembolism - etiology - therapy |
2 |
|
thrombus aspiration |
2 |
|
tilt-table test - adverse effects - methods |
2 |
|
tomography, x-ray computed - methods |
2 |
|
tricuspid valve disease |
2 |
|
tubulin modulators - administration & dosage |
2 |
|
ultrasonography, interventional |
2 |
|
vagal syndromes |
2 |
|
valvular heart surgery |
2 |
|
vascular disease |
2 |
|
vein occlusion |
2 |
|
venous thrombosis - radiography |
2 |
|
ventricular dysfunction, left - epidemiology - physiopathology - ultrasonography |
2 |
|
ventricular tachycardia |
2 |
|
virtual histology |
2 |
|
vitamin d deficiency |
2 |
|
*cardiac catheterization |
1 |
|
*echocardiography, doppler |
1 |
|
*electrocardiography |
1 |
|
*heart valve prosthesis |
1 |
|
*ventricular remodeling |
1 |
|
adverse events |
1 |
|
angiographic restenosis |
1 |
|
animals, newborn |
1 |
|
anthracycline-based chemotherapy |
1 |
|
anticoagulation |
1 |
|
aorta - pathology |
1 |
|
aorta, thoracic - abnormalities - radiography |
1 |
|
aortic aneurysm, thoracic - radiography |
1 |
|
aortic regurgitation |
1 |
|
aortic stenosis |
1 |
|
aortic valve - pathology - surgery |
1 |
|
aortic valve stenosis |
1 |
|
aortic valve stenosis - pathology - physiopathology - surgery |
1 |
|
aortic valve stenosis/mortality/physiopathology/*surgery/*ultrasonography |
1 |
|
aortic valve/physiopathology/*surgery/*ultrasonography |
1 |
|
aortography |
1 |
|
apoptosis |
1 |
|
apoptosis/*drug effects |
1 |
|
arrhythmias, cardiac - diagnosis - etiology - therapy - ultrasonography |
1 |
|
asia |
1 |
|
atherosclerosis - complications - epidemiology - radiography |
1 |
|
behçet's disease |
1 |
|
bifurcation stenoses |
1 |
|
bifurcation stenosis |
1 |
|
brachytherapy - adverse effects |
1 |
|
cardiac remodelling |
1 |
|
cardiac resynchronization therapy |
1 |
|
cardiac resynchronization therapy - methods |
1 |
|
cardiac-gated single-photon emission computer-assisted tomography |
1 |
|
cardiomyopathies |
1 |
|
cardiomyopathies - diagnosis |
1 |
|
cardiomyopathies - diagnosis - physiopathology |
1 |
|
cardiomyopathies - etiology - physiopathology - surgery |
1 |
|
cardiovascular and renal protection |
1 |
|
carotenoids/*pharmacology |
1 |
|
carotid artery diseases/*epidemiology |
1 |
|
catecholamines |
1 |
|
cause of death |
1 |
|
cell hypoxia/drug effects |
1 |
|
cell survival/drug effects |
1 |
|
cicatrix - diagnosis |
1 |
|
clinical assessment |
1 |
|
combined modality therapy |
1 |
|
complete atrioventricular block |
1 |
|
computational angiography–derived fractional flow reserve |
1 |
|
confidence intervals |
1 |
|
coronary angiography - methods |
1 |
|
coronary artery disease - radiography |
1 |
|
coronary artery disease - radiography - therapy |
1 |
|
coronary artery disease/*epidemiology |
1 |
|
coronary disease - complications - epidemiology - radiography |
1 |
|
coronary physiology |
1 |
|
coronary restenosis - diagnosis - therapy |
1 |
|
coronary restenosis - etiology - radiography - therapy |
1 |
|
coronary stenosis - diagnosis - therapy |
1 |
|
coronary stenosis/*complications/physiopathology |
1 |
|
cushing syndrome - complications - physiopathology - surgery |
1 |
|
cytoprotection/*drug effects |
1 |
|
death, sudden, cardiac - epidemiology - etiology |
1 |
|
deep vein thrombosis |
1 |
|
diabetes mellitus - epidemiology |
1 |
|
diagnostic imaging |
1 |
|
diverging wave |
1 |
|
drug delivery systems |
1 |
|
drug-eluting balloon |
1 |
|
drug-eluting stent |
1 |
|
echocardiography, three-dimensional - methods |
1 |
|
echocardiography/*methods |
1 |
|
endothelial cells - cytology |
1 |
|
essential hypertension |
1 |
|
fibrosis - etiology - physiopathology - surgery |
1 |
|
global |
1 |
|
global health |
1 |
|
glycemic status |
1 |
|
haemoglobin a1c variability |
1 |
|
heart catheterization - methods |
1 |
|
heart failure - complications |
1 |
|
heart failure - mortality - surgery - ultrasonography |
1 |
|
heart failure/physiopathology/*therapy/ultrasonography |
1 |
|
heart valve prosthesis implantation - methods |
1 |
|
heart valve prosthesis implantation/*methods/mortality |
1 |
|
heart ventricles - surgery - ultrasonography |
1 |
|
heart ventricles/physiopathology/*ultrasonography |
1 |
|
hematopoietic stem cells - cytology |
1 |
|
hypertension - epidemiology |
1 |
|
hypertrophy, left ventricular - etiology - physiopathology - surgery |
1 |
|
in-stent restenosis |
1 |
|
invasive physiologic assessment |
1 |
|
iron compounds |
1 |
|
iron deficiency |
1 |
|
ischemia/reperfusion |
1 |
|
isolated side branch ostium stenosis |
1 |
|
itga1 |
1 |
|
kidney failure, chronic - diagnosis - epidemiology - etiology |
1 |
|
left ventricle |
1 |
|
left ventricular structure |
1 |
|
length of stay |
1 |
|
longitudinal changes |
1 |
|
magnetic resonance angiography |
1 |
|
major adverse cardiac events |
1 |
|
malignancy |
1 |
|
mice |
1 |
|
mice, inbred c57bl |
1 |
|
mitochondria/*drug effects/metabolism |
1 |
|
mitochondrial membrane transport proteins/chemistry/metabolism |
1 |
|
mitral valve insufficiency - physiopathology - surgery |
1 |
|
multimodality imaging |
1 |
|
myocardial infarction - diagnosis |
1 |
|
myocardial infarction/etiology/*physiopathology |
1 |
|
myocardial ischemia - mortality - ultrasonography |
1 |
|
myocardial revascularization/*methods |
1 |
|
myocytes, cardiac/*cytology/*drug effects/metabolism |
1 |
|
near-field clutter |
1 |
|
no-reflow myocardial viability |
1 |
|
nonobstructive coronary artery disease |
1 |
|
nuclear imaging |
1 |
|
oxidative stress/drug effects |
1 |
|
oxygen/*metabolism |
1 |
|
pacemaker pocket infection |
1 |
|
paclitaxel-eluting balloon |
1 |
|
pd150606 |
1 |
|
perivalvular leakage |
1 |
|
plaque rupture |
1 |
|
plasma integrin α1 |
1 |
|
protein conformation/drug effects |
1 |
|
psoriasis/*epidemiology |
1 |
|
pulmonary disease, chronic obstructive - epidemiology |
1 |
|
pulmonary embolism |
1 |
|
quality improvement |
1 |
|
radial artery |
1 |
|
randomized singular value decomposition |
1 |
|
registry |
1 |
|
risk assessment - methods |
1 |
|
saphenous vein graft lesion |
1 |
|
signal transduction/drug effects |
1 |
|
sirolimus-coated balloon |
1 |
|
small vessel disease |
1 |
|
speckle tracking |
1 |
|
spironolactone |
1 |
|
stroke volume |
1 |
|
stroke volume/physiology |
1 |
|
subclavian artery - abnormalities - radiography |
1 |
|
systole |
1 |
|
tavi |
1 |
|
ultrafast ultrasound |
1 |
|
urinary free cortisol |
1 |
|
vascular brachytherapy |
1 |
|
ventricular dysfunction, left |
1 |
|
ventricular dysfunction, left - diagnosis - physiopathology |
1 |
|
ventricular dysfunction, left - etiology - physiopathology - surgery |
1 |
|
ventricular dysfunction, left - pathology - physiopathology |
1 |
|
ventricular dysfunction, left - physiopathology - therapy - ultrasonography |
1 |
|
ventricular function, left |
1 |
|
ventricular function, left/*physiology |
1 |
|
ventricular function, left/physiology |
1 |
|
μ-calpain |
1 |
